[1] De la Fuente M, Miquel J. An update of the oxidation-inflammation theory of aging: The involvement of the immune system in oxi-inflamm-aging. Curr Pharm Des, 2009, 15(26): 3003-3026.[2] Sebastiani1 P, Solovieff1 N, DeWan AT, Walsh KM, Puca A, Hartley SW, Melista E, Andersen S, Dworkis DA, Wilk JB, Myers RH, Steinberg MH, Montano M, Baldwin CT, Hoh J, Perls TT. Genetic signatures of exceptional lon-gevity in humans. PloS One, 2012, 7(1): e29848.[3] Ruan QW, Liu F, Gao ZJ, Kong DQ, Hu XN, Shi DM, Bao ZJ, Yu ZW. The anti-inflammaging and hepatoprotective effects of huperzine A in D-galactose-treated rat. Mech Ageing Dev, 2013; 134(3-4): 89-97.[4] Naumova E, Ivannova M, Pawelec G. Immunogenetics of ageing. Int J Immunogenet, 2011, 38(5): 373-381.[5] 孔放, 张根发, 吕泽平, 孙亮, 郑陈光, 梁积英, 朱小泉, 杨泽. 人类长寿相关基因研究进展. 遗传, 2006, 28(7): 874-879.[6] 俞卓伟, 保志军, 阮清伟, 马永兴. 氧化应激-炎症-衰老及其与ApoE基因相关性研究进展. 生理学报, 2013, 65(3): 338-346.[7] Naumova E, Ivanova M, Pawelec G, Constantinescu I, Bogunia-Kubik K, Lange A, Oguz F, Ozdilli K, Franceschi C, Caruso C, Mishra M, Middleton D. 16th IHIW: Immunogenetics of aging. Int J Immunogenet, 2013, 40(1): 77-81.[8] Fulop T, Larbi A, Kotb R, de Angelis F, Pawelec G. Aging, immunity, and cancer. Discov Med, 2011, 11(61): 537-550.[9] Balistreri CR, Candore G, Accardi G, Bova M, Buffa S, Bulati M, Forte GI, Listì F, Martorana A, Palmeri M, Pel-licanò M, Vaccarino L, Scola L, Lio D, Colonna-Romano G. Genetics of longevity. data from the studies on Sicilian centenarians. Immun Ageing, 2012, 9(1): 8.[10] Hurme M, Kivimaki M, Pertovaara M, Lehtimäki T, Karhunen PJ, Jylhä M, Hervonen A, Eklund C. CRP gene is involved in the regulation of human longevity: a follow-up study in finnish nonagenarians. Mech Ageing Dev, 2007, 128(10): 574-576.[11] Laine M, Jarva H, Seitsonen S, Haapasalo K, Lehtinen MJ, Lindeman N, Anderson DH, Johnson PT, Jarvela I, Jokiranta TS, Hageman GS, Immonen I, Meri S. Y402H polymorphism of complement factor H affects binding af-finity to C-reactive protein. J Immunol, 2007, 178(6): 3831-3836.[12] Jylhävä J, Eklund C, Jylhä M, Hervonen A, Lehtimäki T, Karhunen P, Hurme M. Complement factor H 402His variant confers an increased mortality risk in finnish nonagenarians: the vitality 90+ study. Exp Gerontol, 2009, 44(4): 297-299.[13] Naumova E, Pawelec G, Ivanova M, Constantinescu I, Bogunia-Kubik K, Lange A, Qguz F, Carin M. 14th International HLA and Immunogenetics Workshop: report on the immunogenetics of aging. Tissue Antigens, 2007, 69(Suppl 1): 304-310.[14] Becerril EV, Fern?ndez RG, Torres LP, Lacomba MS, Galera JMG. HLA B27 as predisposition factor to suffer age related macular degeneration. Cell Mol Immunol, 2009, 6(4): 303-307.[15] Listì F, Caruso C, Colonna-Romano G, Lio D, Nuzzo D, Candore G. HLA and KIR frequencies in Sicilian Cente-narians. Rejuvenation Res, 2010, 13(2-3): 314-318.[16] Iannitti T, Palmieri B. Inflammation and genetics: an in-sight in the centenarian model. Hum Biol, 2011, 83(4): 531-559.[17] Jylhävä J, Hurme M. Gene variants as determinants of Longevity: focus on the inflammatory factors. Pflugers Arch, 2010, 459(2): 239-246.[18] Naumova E, Ivanova M, Pawelec G, Constantinescu I, Bogunia-Kubik K, Lange A, Qguz F, Carin M, Franceschi C, Caruso C, Middleton D. ‘Immunogenetics of Aging’: report on the activities of the 15th international HLA and immunogenetics working group and 15th international HLA and immunogenetics workshop. Tissue Antigens, 2011, 77(3): 187-192.[19] Scola L, Licastro F, Chiappelli M, Franceschi C, Grimaldi LM, Crivello A, Colonna-Romano G, Candore G, Lio D, Caruso C. Allele frequencies of +874T → A single nu-cleotide polymorphism at the first intron of IFN-gamma gene in Alzheimer's disease patients. Aging Clin Exp Res, 2003, 15(4): 292-295.[20] Vaccarino L, Vitale S, Caruso M, Palmeri M, Scola L, Bova M, Caruso C, Massenti MF, Vitale F, Novo S, Lio D, Forte GI. Myocardial infarction marker levels are influenced by prothrombin and tumor necrosis factor-α gene polymorphisms in young patients. Cytokine, 2013, 61(1): 218-222.[21] Khabour OF, Barnawi JM. Association of longevity with IL-10-1082 G⁄A and TNF-α-308 G⁄A polymorphisms. Int J Immunogenet, 2010, 37(4): 293-298.[22] Balistreri CR, Colonna-Romano G, Lio D, Candore G, Caruso C. TLR4 polymorphisms and ageing: implications for the pathophysiology of age-related diseases. J Clin Immunol, 2009, 29(4): 406-415.[23] Listì F, Caruso M, Incalcaterra E, Hoffmann E, Caimi G, Balistreri CR, Vasto S, Scafidi V, Caruso C, Candore G. Pro-inflammatory gene variants in myocardial infarction and longevity: implications for pharmacogenomics. Curr Pharm Des, 2008, 14(26): 2678-2685.[24] Balistreri CR, Grimaldi MP, Chiappelli M, Licastro F, Castiglia L, Listì F, Vasto S, Lio D, Caruso C, Candore G. Association between the polymorphisms of TLR4 and CD14 genes and Alzheimer's disease. Curr Pharm Des, 2008, 14(26): 2672-2677.[25] Balistreri CR, Caruso C, Carruba G, Miceli V, Campisi I, Listì F, Lio D, Colonna-Romano G, Candore G. A pilot study on prostate cancer risk and pro-inflammatory geno-types: pathophysiology and therapeutic implications. Curr Pharm Des, 2010, 16(6): 718-724.[26] Aïd S, Bosetti F. Targeting cyclooxygenases-1 and -2 in neuroinflammation: therapeutic implications. Biochimie, 2011, 93(1): 46-51.[27] Dwyer JH, Allayee H, Dwyer KM, Fan J, Wu HY, Mar R, Lusis AJ, Mehrabian M. Arachidonate 5-lipoxygenase promoter genotype, dietary arachidonic acid, and athero-sclerosis. N Engl J Med, 2004, 350(1): 29-37.[28] Cipollone F, Fazia ML. COX-2 and atherosclerosis. J Cardiovasc Pharmacol, 2006, 47(Suppl. 1): S26-S36.[29] Papafili A, Hill MR, Brull DJ, McAnulty RJ, Marshall RP, Humphries SE, Laurent GJ. Common promoter variant in cyclooxygenase-2 represses gene expression: evidence of role in acute-phase inflammatory response. Arterioscler Thromb Vasc Biol, 2002, 22(10): 1631-1636.[30] Balistreri CR, Caruso C, Grimaldi MP, Listì F, Vasto S, Orlando V, Campagna AM, Lio D, Candore G. CCR5 receptor: biologic and genetic implications in age-related diseases. Ann N Y Acad Sci, 2007, 1100(1): 162-172.[31] Balistreri CR, Candore G, Caruso M, Incalcaterra E, Franceschi C, Caruso C. Role of polymorphisms of CC-chemokine receptor-5 gene in acute myocardial infarction and biological implications for longevity. Haematologica, 2008, 93(4): 637-638.[32] Laplana M, Fibla J. Distribution of functional polymor-phic variants of inflammation-related genes RANTES and CCR5 in long-lived individuals. Cytokine, 2012, 58(1): 10-13.[33] Maxwell LD, Ross OA, Curran MD, Rea IM, Middleton D. Investigation of KIR diversity in immunosenecence and longevity within the Irish population. Exp Gerontol, 2004, 39(8): 1223-1232.[34] Li G, Yu MC, Weyand CM, Goronzy JJ. Epigenetic regu-lation of killer immunoglobulin-like receptor expression in T cells. Blood, 2009, 114(16): 3422-3430.[35] Liu Y, Chen YX, Richardson B. Decreased DNA methyl-transferase levels contribute to abnormal gene expression in “senescent” CD4+CD28-T cells. Clin Immunol, 2009, 132(2): 257-265.[36] Jobim M, Chagastelles P, Salim PH, Portela P, Wilson TJ, Curti AG, Jobim MR, João DA, Nardi NB, Tschiedel B, Jobim LF, Roesler R, Schwartsmann G. Association of killer cell immunoglobulin-like receptors and human leu-kocyte antigen-C genotypes in South Brazilian with type 1 diabetes. Hum Immunol, 2010, 71(8): 799-803.[37] Zaia JA, Sun JY, Gallez-Hawkins GM, Thao L, Oki A, Lacey SF, Dagis A, Palmer J, Diamond DJ, Forman SJ, Senitzer D. The effect of single and combined activating killer immunoglobulin-like receptor genotypes on cy-tomegalovirus infection and immunity after hematopoietic cell transplantation. Biol Blood Marrow Transplant, 2009, 15(3): 315-325. |